Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Comera Life Sciences Holdings, Inc.CMRA · Entity 94670 | Director · See Remarks. | September 27, 2023 | September 28, 2023 |
| FENNEC PHARMACEUTICALS INC.FENC · Entity 5601 | Director · Chief Executive Officer | October 12, 2026 | October 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Comera Life Sciences Holdings, Inc.
Report date September 27, 2023 · Filed September 28, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $0.38 · Expires 2033-09-27 | Direct | 600,000 |
Reported balance
After 2023-09-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-09-27 · Grant · Acquired 600,000 · Balance 600,000 F1: 25% of the shares underlying the stock option vest on September 27, 2024, with the remaining shares vesting on a monthly basis on the 27th day of each month thereafter, in each case, subject to continuous service to the issuer, such that the option shall be fully vested on September 27, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares underlying the stock option vest on September 27, 2024, with the remaining shares vesting on a monthly basis on the 27th day of each month thereafter, in each case, subject to continuous service to the issuer, such that the option shall be fully vested on September 27, 2027.
FENNEC PHARMACEUTICALS INC.
Report date October 12, 2026 · Filed October 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 69,685 |
Reported balance
After 2026-10-12 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-10-12 · Grant · Acquired 2,224 · Balance 69,685 F1: The Issuer's common shares were acquired pursuant to the Fennec Pharmaceuticals Inc. Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of April 9, 2026 through October 12, 2026. F2: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on the Nasdaq Capital Market on April 9, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The Issuer's common shares were acquired pursuant to the Fennec Pharmaceuticals Inc. Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of April 9, 2026 through October 12, 2026.
F2: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on the Nasdaq Capital Market on April 9, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 12, 2026 Filed Oct 13, 2026 20:05 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantCommon Shares | 2,224 | $5.53 | $12,298.72 |
DisclosureSEC source: 0001926254-26-000018 · form4-10132026_041008.xml · nonDerivative · entry 1 Hackman Jeffrey S. · CIK 0001926254 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,685 F1 · security: The Issuer's common shares were acquired pursuant to the Fennec Pharmaceuticals Inc. Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of April 9, 2026 through October 12, 2026. F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on the Nasdaq Capital Market on April 9, 2026. Read SEC document |
| September 30, 2026 Filed Oct 2, 2026 00:05 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantCommon Shares | 1,159 | $0.00 | $0.00 |
DisclosureSEC source: 0001926254-26-000016 · form4-10012026_041005.xml · nonDerivative · entry 1 Hackman Jeffrey S. · CIK 0001926254 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,461 F1 · security: Represents shares released from restriction from shares awarded 3/28/2025. Read SEC document |
| August 31, 2026 Filed Sep 1, 2026 00:10 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantCommon Shares | 1,159 | $0.00 | $0.00 |
DisclosureSEC source: 0001926254-26-000014 · form4-09012026_120929.xml · nonDerivative · entry 1 Hackman Jeffrey S. · CIK 0001926254 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,302 F1 · security: Represents shares released from restriction from shares awarded 3/28/2025. Read SEC document |
| July 31, 2026 Filed Aug 3, 2026 20:05 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantCommon Shares | 1,159 | $0.00 | $0.00 |
DisclosureSEC source: 0001926254-26-000012 · form4-08032026_040806.xml · nonDerivative · entry 1 Hackman Jeffrey S. · CIK 0001926254 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,143 F1 · security: Represents shares released from restriction from shares awarded 3/28/2025. Read SEC document |
| June 30, 2026 Filed Jul 1, 2026 20:36 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantCommon Shares | 1,159 | $0.00 | $0.00 |
DisclosureSEC source: 0001926254-26-000010 · form4-07012026_080713.xml · nonDerivative · entry 1 Hackman Jeffrey S. · CIK 0001926254 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,984 F1 · security: Represents shares released from restriction from shares awarded 3/28/2025. Read SEC document |
| May 31, 2026 Filed Jun 1, 2026 20:05 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantCommon Shares | 1,159 | $0.00 | $0.00 |
DisclosureSEC source: 0001926254-26-000008 · form4-06012026_040603.xml · nonDerivative · entry 1 Hackman Jeffrey S. · CIK 0001926254 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,825 F1 · security: Represents shares released from restriction from shares awarded 3/28/2025. Read SEC document |
| April 30, 2026 Filed May 1, 2026 20:05 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Exercise / conversionCommon Shares | 1,159 | $0.00 | $0.00 |
DisclosureSEC source: 0001926254-26-000006 · form4-05012026_040503.xml · nonDerivative · entry 1 Hackman Jeffrey S. · CIK 0001926254 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,666 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents shares released from restriction from shares awarded 3/28/2025. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 20:05 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantStock Options · Derivative | 200,000 | $5.77 Strike: $5.77 | $1,154,000.00 |
DisclosureSEC source: 0001926254-26-000004 · form4-04022026_040412.xml · derivative · entry 4 Hackman Jeffrey S. · CIK 0001926254 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 725,000 Underlying: Common Shares · 200,000 shares Expires 2036-03-31 F3 · security: On March 31, 2026, granted incentive stock options to purchase 200,000 shares of the issuers common shares pursuant to the Issuer's 2020 Equity Incentive Plan. F4 · derivative.exercise_date: One-third of the shares subject to this option may be exercised as of March 31, 2027 ("Vesting Commencement Date"). One twenty-fourth of the shares subject to this option shall vest and may be exercised as of the last day of each month following the Vesting Commencement Date. As of March 31, 2029, 100% of the total number of shares subject to this option shall be vested. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 20:05 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Exercise / conversionCommon Shares | 1,159 | $0.00 | $0.00 |
DisclosureSEC source: 0001926254-26-000004 · form4-04022026_040412.xml · nonDerivative · entry 2 Hackman Jeffrey S. · CIK 0001926254 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,564 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Represents shares released from restriction from shares awarded 3/28/2025. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 20:05 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Exercise / conversionCommon Shares | 16,695 | $0.00 | $0.00 |
DisclosureSEC source: 0001926254-26-000004 · form4-04022026_040412.xml · nonDerivative · entry 1 Hackman Jeffrey S. · CIK 0001926254 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,405 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents settlement of PSUs that vested on March 31, 2026. Read SEC document |
| March 28, 2026 Filed Apr 2, 2026 20:05 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Exercise / conversionCommon Shares | 13,943 | $0.00 | $0.00 |
DisclosureSEC source: 0001926254-26-000004 · form4-04022026_040412.xml · nonDerivative · entry 3 Hackman Jeffrey S. · CIK 0001926254 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,507 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Represents shares released from restriction from shares awarded 3/28/2025. Read SEC document |
| February 18, 2026 Filed Feb 19, 2026 23:44 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Exercise / conversionCommon Shares | 13,710 | $0.00 | $0.00 |
DisclosureSEC source: 0001926254-26-000002 · form4-02192026_110240.xml · nonDerivative · entry 1 Hackman Jeffrey S. · CIK 0001926254 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,710 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents settlement of PSUs that vested on February 18, 2026. Read SEC document |
| May 19, 2025 Filed May 19, 2025 21:42 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | PurchaseCommon Shares | 13,965 | $6.99 | $97,615.35 |
DisclosureSEC source: 0001415889-25-013673 · form4-05192025_090517.xml · nonDerivative · entry 2 Hackman Jeffrey S. · CIK 0001926254 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 F1 · security: Transaction Code P - Open market or private purchase of non-derivative or derivative security Read SEC document |
| May 16, 2025 Filed May 19, 2025 21:42 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | PurchaseCommon Shares | 1,035 | $6.75 | $6,986.25 |
DisclosureSEC source: 0001415889-25-013673 · form4-05192025_090517.xml · nonDerivative · entry 1 Hackman Jeffrey S. · CIK 0001926254 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,035 F1 · security: Transaction Code P - Open market or private purchase of non-derivative or derivative security Read SEC document |
| March 28, 2025 Filed Apr 3, 2025 23:13 UTC Amendment | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantStock Options · Derivative | 50,000 | $0.00 Strike: $6.50 | $0.00 |
DisclosureSEC source: 0001415889-25-010065 · form4a-04032025_110440.xml · derivative · entry 2 Hackman Jeffrey S. · CIK 0001926254 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 525,000 Underlying: Common Shares · 50,000 shares Expires 2035-03-28 F3 · security: On March 28, 2025, Jeffrey Hackman was granted incentive stock options to purchase 50,000 shares of the issuers common shares pursuant to the Issuer's 2020 Equity Incentive Plan. F4 · derivative.exercise_date: One-third of the shares subject to this option may be exercised as of March 28, 2026 ("Vesting Commencement Date"). One twenty-fourth of the shares subject to this option shall vest and may be exercised as of the last day of each month following the Vesting Commencement Date. As of February 29, 2028, 100% of the total number of shares subject to this option shall be vested Read SEC document |
| March 28, 2025 Filed Apr 3, 2025 23:13 UTC Amendment | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantRestricted Share Unit · Derivative | 75,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-010065 · form4a-04032025_110440.xml · derivative · entry 1 Hackman Jeffrey S. · CIK 0001926254 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 475,000 Underlying: Common Shares · 75,000 shares Expires 2035-03-28 F1 · security: On March 28, 2025, Jeffrey Hackman was awarded restricted share units to acquire 75,000 shares of the issuer's common shares pursuant to the issuer's 2020 Equity Incentive Plan F2 · derivative.exercise_date: One-third of the shares subject to this award shall be released from restriction as of March 28, 2026 (the "Vesting Commencement Date"). One twenty-fourth of the shares subject to this award may be released from restriction as of the last day of each month following the Vesting Commencement Date. As of February 29, 2028 and thereafter, 100% of the total number of shares subject to this award shall be released from restriction. Read SEC document |
| March 28, 2025 Filed Apr 3, 2025 22:12 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantStock Options · Derivative | 50,000 | $0.00 Strike: $6.50 | $0.00 |
DisclosureSEC source: 0001415889-25-010057 · form4-04032025_100450.xml · derivative · entry 2 Hackman Jeffrey S. · CIK 0001926254 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 450,000 Underlying: Common Shares · 50,000 shares Expires 2035-03-28 F3 · security: On March 28, 2025, Jeffrey Hackman was granted incentive stock options to purchase 50,000 shares of the issuers common shares pursuant to the Issuer's 2020 Equity Incentive Plan. F4 · derivative.exercise_date: One-third of the shares subject to this option may be exercised as of March 28, 2026 ("Vesting Commencement Date"). One twenty-fourth of the shares subject to this option shall vest and may be exercised as of the last day of each month following the Vesting Commencement Date. As of February 29, 2028, 100% of the total number of shares subject to this option shall be vested Read SEC document |
| March 28, 2025 Filed Apr 3, 2025 22:12 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantRestricted Share Unit · Derivative | 75,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-010057 · form4-04032025_100450.xml · derivative · entry 1 Hackman Jeffrey S. · CIK 0001926254 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Shares · 75,000 shares Expires 2035-03-28 F1 · security: On March 28, 2025, Jeffrey Hackman was awarded restricted share units to acquire 75,000 shares of the issuer's common shares pursuant to the issuer's 2020 Equity Incentive Plan F2 · derivative.exercise_date: One-third of the shares subject to this award shall be released from restriction as of March 28, 2026 (the "Vesting Commencement Date"). One twenty-fourth of the shares subject to this award may be released from restriction as of the last day of each month following the Vesting Commencement Date. As of February 29, 2028 and thereafter, 100% of the total number of shares subject to this award shall be released from restriction. Read SEC document |
| August 15, 2024 Filed Aug 19, 2024 22:59 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantStock Options · Derivative | 400,000 | $5.58 Strike: $5.58 | $2,232,000.00 |
DisclosureSEC source: 0001415889-24-021637 · form4-08192024_100825.xml · derivative · entry 1 Hackman Jeffrey S. · CIK 0001926254 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Shares · 400,000 shares Expires 2034-08-05 F1 · security: On August 15, 2024, Jeffrey Hackman was granted incentive stock options to purchase 400,000 shares of the issuers common shares pursuant to the Issuer's 2020 Equity Incentive Plan. F2 · derivative.exercise_date: One-third of the shares subject to this option may be exercised as of August 5, 2025 ("Vesting Commencement Date"). One twenty-fourth of the shares subject to this option shall vest and may be exercised as of the last day of each month following the Vesting Commencement Date. As of August 5, 2027, 100% of the total number of shares subject to this option shall be vested. Read SEC document |
| September 27, 2023 Filed Sep 28, 2023 16:06 UTC | Comera Life Sciences Holdings, Inc. CMRA · Entity 94670 | GrantStock Option (Right to Purchase) · Derivative | 600,000 | $0.00 Strike: $0.38 | $0.00 |
DisclosureSEC source: 0001062993-23-018577 · form4.xml · derivative · entry 1 Hackman Jeffrey S. · CIK 0001926254 · Director · See Remarks. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 600,000 Underlying: Common Stock · 600,000 shares Expires 2033-09-27 F1 · derivative.exercise_date: 25% of the shares underlying the stock option vest on September 27, 2024, with the remaining shares vesting on a monthly basis on the 27th day of each month thereafter, in each case, subject to continuous service to the issuer, such that the option shall be fully vested on September 27, 2027. Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 18:20 UTC | Comera Life Sciences Holdings, Inc. CMRA · Entity 94670 | GrantStock Option (Right to Purchase) · Derivative | 100,000 | $0.00 Strike: $1.30 | $0.00 |
DisclosureSEC source: 0001062993-23-003833 · form4.xml · derivative · entry 1 Hackman Jeffrey S. · CIK 0001926254 · Director · See Remarks. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2033-02-14 F1 · derivative.exercise_date: 25% of the shares underlying the stock option vest on February 14, 2024, with the remaining shares vesting on a monthly basis on the 14th day of each month thereafter, in each case, subject to continuous service to the issuer, such that the option shall be fully vested on February 14, 2027. Read SEC document |
| September 09, 2022 Filed Sep 12, 2022 17:23 UTC | Comera Life Sciences Holdings, Inc. CMRA · Entity 94670 | PurchaseCommon Stock | 47,600 | $2.06 | $98,056.00 |
DisclosureSEC source: 0001062993-22-019482 · form4.xml · nonDerivative · entry 1 Hackman Jeffrey S. · CIK 0001926254 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,600 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.00 to $2.10, inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. Read SEC document |
| August 09, 2022 Filed Aug 11, 2022 18:14 UTC | Comera Life Sciences Holdings, Inc. CMRA · Entity 94670 | GrantStock Option (Right to Purchase) · Derivative | 300,000 | $0.00 Strike: $2.77 | $0.00 |
DisclosureSEC source: 0001062993-22-017760 · form4.xml · derivative · entry 1 Hackman Jeffrey S. · CIK 0001926254 · Director · See Remarks. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2032-08-09 F1 · derivative.exercise_date: The stock option shall vest over four (4) years, with twenty-five percent (25%) of the shares of Common Stock underlying the option vesting on August 9, 2023 and the remainder vesting in equal monthly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.